Black Diamond Therapeutics (BDTX) shares were climbing Tuesday, up 3.51% in premarket trading to $2.36, after the company shared some encouraging news from its cancer drug pipeline.
The clinical-stage oncology company recently reported Phase 2 data for silevertinib, its lead candidate, in patients with frontline non-small cell lung cancer (NSCLC) who have EGFR non-classical mutations. The results, the company says, support silevertinib's potential as a practice-changing treatment, with promising preliminary progression-free survival data. Those findings are set to be presented at the ASCO Annual Meeting on May 30, 2026.
Earlier this month, Black Diamond reported first-quarter earnings that beat Wall Street expectations. The company posted a loss of $0.16 per share, better than the $0.18 loss analysts had forecast. Research and development expenses fell to $7 million from $10.5 million a year ago, largely due to progress in the Phase 2 silevertinib trial and the outlicensing of BDTX-4933 as the company sharpens its focus on silevertinib. As of March 31, the company had $118.3 million in cash, cash equivalents, and investments, which management says should fund operations into the second half of 2028.
So what does the technical picture look like for BDTX? At $2.36, the stock is trading 16.2% below its 20-day simple moving average (SMA) of $2.84 and 9.7% below its 50-day SMA of $2.63. Over the past 12 months, the stock is up 11.22%, showing some resilience despite recent volatility. The moving averages tell a mixed story: the 20-day SMA is above the 50-day SMA, which is a bullish short-term signal. But the 50-day SMA is below the 200-day SMA, forming a death cross that suggests longer-term bearish sentiment. The MACD is currently below its signal line, indicating that momentum is fading—something traders might want to keep an eye on.
Black Diamond Therapeutics is a clinical-stage oncology company developing what it calls MasterKey therapies that target families of oncogenic mutations. Its foundation is built on a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its lead program, silevertinib (formerly BDTX-1535), is in a Phase 2 trial for EGFR mutant NSCLC.
Analysts are broadly bullish on the stock. The average price target is $11.00, with a Buy rating. Recent analyst moves include BTIG raising its forecast to $11.00 on April 29, Wedbush boosting its target to $14.00 on March 17, and Piper Sandler lowering its target to $8.00 on January 16—though still maintaining an Overweight rating.
With the ASCO presentation just days away, all eyes will be on silevertinib's data and whether it can live up to the hype.






.jpeg)







